Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,issuanceOfStock,repurchaseOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,market,currency,twoHundredDayAverageChangePercent,exchangeDataDelayedBy,marketState,exchange,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,gmtOffSetMilliseconds,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,shortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Aug 12, 2021) 4","Short Ratio (Aug 12, 2021) 4","Short % of Float (Aug 12, 2021) 4","Short % of Shares Outstanding (Aug 12, 2021) 4","Shares Short (prior month Jul 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,IVA,101375000.0,38630300,6436000,,-8507000,,-8840000,2680000,-1000,-9941000,-9941000,824000,-25000,,,,333000,226000,10167000,227000,1434000,,-8840000,-8840000,881000.0,139668000.0,29964000.0,102256000.0,3788000.0,132220000.0,386000.0,12000.0,-8840000.0,3821000.0,-28958000.0,2750000.0,108703000.0,16068000.0,3000.0,-28958000.0,3172000.0,125417000.0,11817000.0,10062000.0,375000.0,8692000.0,6415000.0,1707000.0,6374000.0,-17000.0,-16000.0,2119000.0,3543000.0,-7781000.0,304000.0,-55000.0,-152000.0,1000.0,-745000.0,-41000.0,,,109349000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,us_market,USD,-0.046563823,0,PRE,NGM,False,False,13.17,1630526385,-0.19999981,13.67,13.67,12.94,3372,15,America/New_York,EDT,2,-1.4958849,12.94 - 13.67,13.37,0.0,0.0,11,8,finmb_273516426,NasdaqGM,Inventiva S.A.,EUR,10550,3471,2.6499996,0.2519011,10.52 - 19.064,-5.893999,-0.30916908,10.52,19.064,-14400000,12.567286,0.60271454,0.047959007,13.813195,-0.64319515,514554528,Inventiva S.A. - American Depos,0.91,,,19.06,10.52,12.57,13.81,10.55k,3.47k,38.63M,,10.21M,0.00%,6.23%,181.84k,24.38,,0.47%,184.9k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-786.95%,-22.64%,-47.01%,4.54M,0.12,-76.10%,4.42M,-34.94M,-35.66M,,,108.7M,2.82,10.09M,9.86,7.80,,-34.79M,-25.12M,Value,21121,Healthcare,95,4,9,"Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.",Daix,33 3 80 44 75 00,9,1609372800,1625097600,8,France,http://www.inventivapharma.com,86400,8,50 rue de Dijon,Biotechnology
t-1,IVA,110276000.0,38630300,4851000,,-8980000,,-8980000,2574000,1505500,-8479000,-8479000,2559500,-29000,,,,0,1747500,10226500,242000,-501000,,-8980000,-8980000,935000.0,139668000.0,27707000.0,111211000.0,3328000.0,138920000.0,386000.0,9127000.0,-33619000.0,3762000.0,4776000.0,1706000.0,106716000.0,13908000.0,16000.0,4776000.0,3282000.0,132997000.0,13521000.0,10037000.0,320000.0,6923000.0,-3631500.0,-53500.0,-3777500.0,-10500.0,43533500.0,26706500.0,-1340500.0,-11709000.0,107000.0,15000.0,-27000.0,-3692000.0,-2835000.0,-146000.0,47236000.0,,119089000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,us_market,USD,-0.046563823,0,PRE,NGM,False,False,13.17,1630526385,-0.19999981,13.67,13.67,12.94,3372,15,America/New_York,EDT,2,-1.4958849,12.94 - 13.67,13.37,0.0,0.0,11,8,finmb_273516426,NasdaqGM,Inventiva S.A.,EUR,10550,3471,2.6499996,0.2519011,10.52 - 19.064,-5.893999,-0.30916908,10.52,19.064,-14400000,12.567286,0.60271454,0.047959007,13.813195,-0.64319515,514554528,Inventiva S.A. - American Depos,0.91,,,19.06,10.52,12.57,13.81,10.55k,3.47k,38.63M,,10.21M,0.00%,6.23%,181.84k,24.38,,0.47%,184.9k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-786.95%,-22.64%,-47.01%,4.54M,0.12,-76.10%,4.42M,-34.94M,-35.66M,,,108.7M,2.82,10.09M,9.86,7.80,,-34.79M,-25.12M,Value,21121,Healthcare,95,4,9,"Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.",Daix,33 3 80 44 75 00,9,1609372800,1625097600,8,France,http://www.inventivapharma.com,86400,8,50 rue de Dijon,Biotechnology
t-2,IVA,110276000.0,38630300,4851000,,-8980000,,-8980000,2574000,1505500,-8479000,-8479000,2559500,-29000,,,,0,1747500,10226500,242000,-501000,,-8980000,-8980000,935000.0,139668000.0,27707000.0,111211000.0,3328000.0,138920000.0,386000.0,9127000.0,-33619000.0,3762000.0,4776000.0,1706000.0,106716000.0,13908000.0,16000.0,4776000.0,3282000.0,132997000.0,13521000.0,10037000.0,320000.0,6923000.0,-3631500.0,-53500.0,-3777500.0,-10500.0,43533500.0,26706500.0,-1340500.0,-11709000.0,107000.0,15000.0,-27000.0,-3692000.0,-2835000.0,-146000.0,47236000.0,,119089000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,us_market,USD,-0.046563823,0,PRE,NGM,False,False,13.17,1630526385,-0.19999981,13.67,13.67,12.94,3372,15,America/New_York,EDT,2,-1.4958849,12.94 - 13.67,13.37,0.0,0.0,11,8,finmb_273516426,NasdaqGM,Inventiva S.A.,EUR,10550,3471,2.6499996,0.2519011,10.52 - 19.064,-5.893999,-0.30916908,10.52,19.064,-14400000,12.567286,0.60271454,0.047959007,13.813195,-0.64319515,514554528,Inventiva S.A. - American Depos,0.91,,,19.06,10.52,12.57,13.81,10.55k,3.47k,38.63M,,10.21M,0.00%,6.23%,181.84k,24.38,,0.47%,184.9k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-786.95%,-22.64%,-47.01%,4.54M,0.12,-76.10%,4.42M,-34.94M,-35.66M,,,108.7M,2.82,10.09M,9.86,7.80,,-34.79M,-25.12M,Value,21121,Healthcare,95,4,9,"Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.",Daix,33 3 80 44 75 00,9,1609372800,1625097600,8,France,http://www.inventivapharma.com,86400,8,50 rue de Dijon,Biotechnology
t-3,IVA,40654000.0,38630300,5595000,,-8861000,,-8861000,1544000,654000,-8860000,-8860000,2375000,-15000,,,,0,823000,9683000,169000,-1000,,-8861000,-8861000,1077000.0,52651000.0,26993000.0,41731000.0,3289000.0,68724000.0,309000.0,,-15659000.0,1789000.0,4430000.0,4137000.0,52273000.0,25204000.0,10017000.0,4430000.0,3341000.0,60169000.0,6725000.0,,349000.0,8529000.0,-1002000.0,1228000.0,-1002000.0,9961000.0,9974000.0,5380000.0,-1340500.0,-3592000.0,330000.0,28000.0,-269000.0,319000.0,3952000.0,-146000.0,47236000.0,-306000.0,34965000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,us_market,USD,-0.046563823,0,PRE,NGM,False,False,13.17,1630526385,-0.19999981,13.67,13.67,12.94,3372,15,America/New_York,EDT,2,-1.4958849,12.94 - 13.67,13.37,0.0,0.0,11,8,finmb_273516426,NasdaqGM,Inventiva S.A.,EUR,10550,3471,2.6499996,0.2519011,10.52 - 19.064,-5.893999,-0.30916908,10.52,19.064,-14400000,12.567286,0.60271454,0.047959007,13.813195,-0.64319515,514554528,Inventiva S.A. - American Depos,0.91,,,19.06,10.52,12.57,13.81,10.55k,3.47k,38.63M,,10.21M,0.00%,6.23%,181.84k,24.38,,0.47%,184.9k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,-786.95%,-22.64%,-47.01%,4.54M,0.12,-76.10%,4.42M,-34.94M,-35.66M,,,108.7M,2.82,10.09M,9.86,7.80,,-34.79M,-25.12M,Value,21121,Healthcare,95,4,9,"Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.",Daix,33 3 80 44 75 00,9,1609372800,1625097600,8,France,http://www.inventivapharma.com,86400,8,50 rue de Dijon,Biotechnology
